We recently partnered with colleagues at Amgen to rescue a promising but low-expressing IgG-scFv bispecific antibody—ultimately achieving an 11-fold titer increase.

Across many bsAb programs, we’ve seen how small sequence differences can create big manufacturing hurdles. In this case, three molecules that shared nearly identical architectures and high sequence homology behaved very differently in CHO cells. A multi-omics analysis—spanning RNA-seq, codon usage, splice-site prediction, and ribosome-pause motif screening—pinpointed subtle liabilities driving the low expression. Targeted sequence edits addressing these issues restored expression dramatically.

Read the paper: https://www.biorxiv.org/content/10.1101/2025.11.10.687454v1.full.pdf

Highlights

  • Virtual Private Network (VPN): Users connect to the cluster, provide some credentials and are then able to access internal tools.
  • Single Sign-On: A tool like Kerberos allows you to use the same account across various components.
  • Home-grown user accounts: You implement an authentication system and users have a separate username/password for your computing infrastructure.

Asimov, the synthetic biology company building a full-stack platform to program living cells, announced today it has been awarded a contract as part of the Defense Advanced Research Projects Agency (DARPA) Automating Scientific Knowledge Extraction (ASKE) opportunity.

Through ASKE, Asimov will work to develop a physics-based artificial intelligence (AI) design engine for biology. The goal of the initiative is to improve the reliability of programming complex cellular behaviors.

“To achieve truly predictive engineering of biology, we require dramatic advances in computer-aided design. Machine learning will be critical to bridge genome-scale experimental data with computational models that accurately capture the underlying biophysics. As genetically engineered systems grow in complexity, they become difficult for humans to design and understand. For simple genetic systems with only a couple of genes, synthetic biologists typically use high-throughput screening and basic optimization algorithms. But to engineer more complex applications in health, materials, and manufacturing, we need radically new algorithms to intelligently design the DNA and simulate cell behavior.”

Alec Nielsen, Phd, Asimov CEO
Over the past 50 years, DARPA has been a world leader in spurring innovation across the field of AI, including statistical-learning and rule-based approaches. We are proud to work with DARPA to advance the state-of-the-art in AI-assisted genetic engineering.

Asimov’s founders previously built a hybrid genetic engineering and computer-aided design platform called Cello to program logic circuit behaviors in cells. The ASKE opportunity will seek to support an ambitious expansion in the types of biological behaviors that can be engineered.

Asimov’s approach will leverage “multi-omics” cellular measurements, structured biological metadata, and novel AI architectures that combine deep learning, reinforcement learning, and mechanistic modeling. Over the past year, the company has ramped up hiring in experimental synthetic biology, machine learning, and data science to accelerate development of their genetic design platform.

Highlights

Headering 3

DARPA recently announced a multi-year investment of $2B into innovative artificial intelligence research called the AI Next campaign. A part of this wide-ranging AI strategy is DARPA’s Artificial Intelligence Exploration program, which was developed to help expeditiously move pioneering AI research from idea to exploration in fewer than 90 days. DARPA’s ASKE opportunity is part of this program and is focused on developing AI technologies that can reason over rich models of complex systems.

“Over the past 50 years, DARPA has been a world leader in spurring innovation across the field of AI, including statistical-learning and rule-based approaches. We are proud to work with DARPA to advance the state-of-the-art in AI-assisted genetic engineering.”

Alec Nielsen, PhD, Asimov CEO
This is some text inside of a div block. Great
Contact us

Chat with our team

Country
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form

Related posts

Blog
announcement
science & technology
Asimov Launches CHO Edge Rapid Pools to Bridge Biologics Discovery and CMC with Predictive Stable Expression

Asimov Launches CHO Edge Rapid Pools to Bridge Biologics Discovery and CMC with Predictive Stable Expression

Asimov Launches CHO Edge Rapid Pools to Bridge Biologics Discovery and CMC with Predictive Stable Expression

December 16, 2025
December 16, 2025
Blog
announcement
science & technology
Asimov Launches Stable AAV Producer Cell Lines, Setting a New Standard for Viral Vector Manufacturing

Asimov Launches Stable AAV Producer Cell Lines, Setting a New Standard for Viral Vector Manufacturing

Asimov Launches Stable AAV Producer Cell Lines, Setting a New Standard for Viral Vector Manufacturing

October 6, 2025
October 6, 2025
Blog
announcement
science & technology
Asimov Announces Cell Line Development Partnership with Ottimo Pharma to Accelerate Cancer Immunotherapy’s Path to Clinic

Asimov Announces Cell Line Development Partnership with Ottimo Pharma to Accelerate Cancer Immunotherapy’s Path to Clinic

Asimov Announces Cell Line Development Partnership with Ottimo Pharma to Accelerate Cancer Immunotherapy’s Path to Clinic

August 27, 2025
August 27, 2025
let’s CONNECT

Excited by the intersection of biology, engineering,
and machine learning?
Get in touch.

Asimov team at their Boston office
Illustration of a white blood cell